Table 1 The relationship between CIL grade and other clinicopathological features
Baseline Characteristics | Total(n,%) | CIL Grade(n,%) | P-value | ||
|---|---|---|---|---|---|
0/I | II/III | IV | |||
Age at diagnosis | 0.215 | ||||
≤ 46 years | 224(50.68) | 20(43.48) | 145(55.77) | 59(43.38) | |
> 46 years | 218(49.32) | 26(56.52) | 115(44.23) | 77(56.62) | |
BMI | 0.860 | ||||
< 25 | 346(78.28) | 33(71.73) | 208(80.00) | 105(77.21) | |
≥ 25 | 96(21.72) | 13(28.26) | 52(20.00) | 31(22.79) | |
Menstrual Status | 0.185 | ||||
premenopausal | 280(63.35) | 31(67.39) | 169(65.00) | 80(58.82) | |
postmenopausal | 162(36.65) | 15(32.61) | 91(35.00) | 56(41.18) | |
HR Status | 0.668 | ||||
Negative | 162(36.65) | 10(21.74) | 105(40.38) | 47(34.56) | |
Positive | 280(63.35) | 36(78.26) | 155(59.62) | 89(65.44) | |
HER2 Status | 0.181 | ||||
Negative | 260(58.82) | 32(69.57) | 152(58.46) | 76(55.88) | |
Positive | 182(41.18) | 14(30.43) | 108(41.54) | 60(44.12) | |
KI67 Indexa | 0.913 | ||||
≤ 15% | 103(23.30) | 13(28.26) | 56(21.54) | 34(25.00) | |
> 15% | 339(76.70) | 33(71.73) | 204(78.46) | 102(75.00) | |
Pathological Grade | 0.982 | ||||
1 + 2 | 220(49.77) | 27(58.69) | 122(46.92) | 71(52.21) | |
3 | 222(50.23) | 19(41.30) | 138(53.08) | 65(47.79) | |
T Stageb | < 0.01 | ||||
T1 | 152(34.39) | 12(26.09) | 83(31.92) | 57(41.91) | |
T2 | 261(59.05) | 30(65.22) | 157(60.38) | 74(54.41) | |
T3 | 29(6.56) | 4(8.70) | 20(7.69) | 5(3.68) | |
N Stageb | < 0.01 | ||||
N0 | 150(33.94) | 16(34.78) | 87(33.46) | 47(34.56) | |
N1 | 141(31.90) | 12(26.09) | 90(34.62) | 39(28.68) | |
N2 | 81(18.33) | 11(23.91) | 39(15.00) | 31(22.79) | |
N3 | 70(15.83) | 7(15.22) | 44(16.92) | 19(13.97) | |
LVI | 0.540 | ||||
No | 225(50.90) | 21(45.65) | 133(51.15) | 71(52.21) | |
Yes | 217(49.10) | 25(54.35) | 127(48.85) | 65(47.79) | |
Chemotherapy | < 0.01 | ||||
TE or TEC | 69(15.61) | 17(36.96) | 24(9.23) | 28(20.59) | |
FEC-T | 59(13.35) | 8(17.39) | 33(12.69) | 18(13.24) | |
AC-T | 314(71.04) | 21(45.65) | 203(78.08) | 90(66.18) | |